Clinical trials: GLP-1
Hyperlipidemias
Plasma Lipoprotein Response to Glucagon-like Peptide-2
Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones.
- Trial name
- GLP-2 Plasma (NCT03422666)
- Testing
- Teduglutide
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion
The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion
The last couple of years it has been shown that bile acids not only acts as simple emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an influence on fat digestion and lipid metabolism, but…
- Trial name
- NCT01656057
- Testing
- Acetaminophen, Metformin, Colesevelam
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Filip Krag Knop
Postural Orthostatic Tachycardia Syndrome (POTS), Healthy
POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS
This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in…
- Trial name
- GA22 (NCT07019519)
- Testing
- GIPR antagonist, GLP-1R antagonist, CCK agonist
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Healthy
Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion
The purpose of this study is to examine the influence of artificial sweeteners (aspartame, acesulfame K, sucralose) and carbohydrate sugars (glucose, fructose) on the release of gastrointestinal satiety hormones in humans.
- Trial name
- NCT00978900
- Testing
- Artificial sweeteners; Carbohydrate Sugars, Water
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy
Physical Training and the Incretin Effect
It is well known that continuous physical exercise leads to a number of changes in the body. Maximal oxygen uptake; the heart's pumping ability and muscle mass and strength increases.
- Trial name
- EXINT2 (NCT01698502)
- Where
- Denmark
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Type 2 Diabetes, Blod Pressure
Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus
Diabetes and high blood pressure are risk factors for developing heart disease. An increase in the number of diabetes patients is expected.
- Conditions
- Type 2 Diabetes, Blod Pressure, Glucagon-like Peptide-1, Human Physiology
- Trial name
- NCT01689051
- Testing
- human glucagon-like peptide 1 (7-36)amide, human glucagon-like peptide 1 (9-36)amide
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Obesity & Overweight, Insulin Resistance Syndrome
SENSILINS: Impact of Cephalic Phase Insulin Release Induced by an Environmental Food Odor Stimulus on Glucose Homeostasis According to Insulin Sensitivity Level
This single-center, randomized, single-blind, 2-period crossover interventional study will evaluate whether exposure to a pleasant food odor 10 minutes before a 75 g oral glucose tolerance test (OGTT) modifies glucose homeostasis…
- Trial name
- SENSILNS (NCT07638111)
- Testing
- Pleasant Food Odor Stimulation, Control Environmental Condition
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Type 1 Diabetes
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases fasting, postprandial and the overall mean glucose concentrations.
- Trial name
- NCT01722266
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Micronutrient Deficiencies
This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including Ozempic (semaglutide) and Saxenda (liraglutide), are gaining traction in treating obesity and its associated diseases due to their capacity to facilitate…
- Trial name
- NCT06981936
- Testing
- Balance Tablet
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
Healthy
a Study of JY09 in Chinese Healthy Subjects
JY09，is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist,constructed with Exendin-4 and human Immunoglobulin G2 (IgG2) Fc fragment.Preclinical studies show that JY09 exhibit the expected GLP-1-mediated…
- Trial name
- NCT02971722
- Testing
- JY09
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Diabetes
Assessment of Intranasal Glucagon on Endogenous Glucose Production
Peripheral glucagon action increases hepatic glucose production. In rodents hypothalamic action of glucagon paradoxically suppresses glucose production.
- Trial name
- NCT02740829
- Testing
- Intranasal glucagon
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Obesity
Carbohydrate Intake and Gut Hormone Release During Exercise
It is well known that following a single session of moderate-to-high intensity exercise individuals experience a temporary suppression of hunger and a delay in the commencement of eating.
- Trial name
- NCT04019418
- Testing
- Maltodextrin (carbohydrate), Exercise, Rest
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Type 1 Diabetes
Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes
The investigators are doing this research study to find out if the type of needle used to administer them affects the speed with which insulin and glucagon get into the blood.
- Trial name
- NCT01684956
- Testing
- Intradermal injection, Subcutaneous injection
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
The Whole-body Protein Synthesis Response to Protein With Amino Acid or Amino Acids
The Effects of LEUVATE on Glycemia, Insulinemia, Aminoacidemia, and Protein Synthesis in GLP-1 RA-treated Adults
GLP-1 receptor agonists have recently emerged as highly effective pharmacological agents for promoting weight loss and improving metabolic health.
- Trial name
- Leuvate001 (NCT07595575)
- Testing
- GLP-1
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nutraceutical Innovations LLC
Obesity
Protein Dose-repsonse Effect on GLP-1, PYY and Appetite in Male Subjects
Dietary protein appears to be the most satiating and thermogenic macronutrient. However, how protein exerts its effect on appetite is not fully known.
- Trial name
- Protein (NCT01561235)
- Testing
- Dose-reponse effect of protein on appetite and appetite-regulating hormones
- Where
- Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Glucagon-like Peptide-1, Smoking Cessation
Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues
Cigarette smoking is the leading preventable cause of premature death worldwide. However smoking is a very difficult addiction to break whereby main reasons for not quitting or relapsing after cessation are the nicotine…
- Conditions
- Glucagon-like Peptide-1, Smoking Cessation, Weight Change, Body, Craving
- Trial name
- SKIP (NCT03204396)
- Testing
- Dulaglutide, 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
- Where
- Switzerland
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Type 2 Diabetes Mellitus
GLP-1 and Hypoglycemia
Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels.
- Trial name
- NCT01858896
- Testing
- Glucagon-Like Peptide- 1 (GLP-1) infusion
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes
SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1 receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal systems in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01744236
- Testing
- Liraglutide, Sitagliptin, Exenatide
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Alcohol Use Disorder
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)
This clinical trial aims to test the effectiveness and safety of semaglutide, a GLP-1 receptor agonist, in treating moderate to severe alcohol use disorder (AUD) in Veterans.
- Trial name
- CRAVE (NCT07218354)
- Testing
- Semaglutide
- Where
- 19 sites in United States
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Diabetes Mellitus, Type 2
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
Glucagon-like peptide 1 (GLP-1) based therapies, such as exenatide, are already successfully employed in the treatment of Type 2 Diabetes (T2DM).
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity
- Trial name
- Braini-Ex (NCT01281228)
- Testing
- exenatide, exenatide + exendin (9-39)
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc